Ivarmacitinib Eased Refractory PCA: Case Report

• by Andrea Surnit

• May 20, 2026

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

• by Kathryn Wighton

• August 28, 2026

• 2 min

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

• by Kathryn Wighton

• August 28, 2026

• 5 min

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

• by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

• June 19, 2026